Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Hypertension in Pregnancy
Interventions: Cardiovascular Sonographic Assessment; Other
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: SBI-100 Ophthalmic Emulsion, 0.5%, SBI-100 Ophthalmic Emulsion, 1.0%, SBI-100 Ophthalmic Emulsion, Placebo; Drug
Lead sponsor: Skye Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Glendale, California • Newport Beach, California • Cranberry Township, Pennsylvania

Conditions: Hypertension
Interventions: DASH Groceries + Weekly Sessions, Groceries + Brochure; Behavioral
Lead sponsor: Washington State University; Other
Eligibility: 18 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 4
States / cities: Purcell, Oklahoma • Rapid City, South Dakota • Seattle, Washington + 1 more

Conditions: HIV
Interventions: MRI, L-NMMA, Acetylcholine; Procedure · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Travoprost ophthalmic solution, 0.0008%, Travoprost ophthalmic solution, 0.001%, Travoprost ophthalmic solution, 0.0012%, TRAVATAN, Vehicle; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Chronic Kidney Disease
Interventions: Not listed
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: San Diego, California

Conditions: Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia, Pulmonary Artery Hypertension
Interventions: BALT GoldbBAL2 Detachable Balloon, Catheter System; Device
Lead sponsor: Rodrigo Ruano; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 2
States / cities: Miami, Florida • Rochester, Minnesota

Conditions: Hypertensive Emergency, Hypertension, Blood Pressure
Interventions: ED-based behavioral intervention, ED usual care plus education; Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 21 Years to 85 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pulmonary Hypertension, Pulmonary Fibrosis
Interventions: Oral treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 79 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 7
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 4 more

Conditions: Hypertension
Interventions: Electronic Intervention; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Systemic Sclerosis-Associated PAH
Interventions: Rituximab, Placebo, CMRI, prednisone, methylprednisolone, diphenhydramine, acetaminophen; Biological · Other · Diagnostic Test + 1 more
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 17
States / cities: Stanford, California • Aurora, Colorado • Iowa City, Iowa + 13 more

Conditions: Pulmnary Hypertension
Interventions: Eko CORE 500 phonocardiogram (PCG) recording, Eko CORE 500 three-lead electrocardiogram (ECG) recording; Diagnostic Test
Lead sponsor: Eko Devices, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,513 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Los Angeles, California • Durham, North Carolina

Conditions: Preeclampsia, Preeclampsia Postpartum
Interventions: Eplerenone; Drug
Lead sponsor: Anna Stanhewicz, PhD; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Hypertension, Resistant to Conventional Therapy
Interventions: Minocycline Hydrochloride, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Diabetes Mellitus Type 2
Interventions: Internet Intervention, Control; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: Not listed
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 2
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama

Conditions: Glaucoma
Interventions: SmartSystem VR Headset perimeter; Diagnostic Test
Lead sponsor: Andrew Pouw, MD; Other
Eligibility: 18 Years to 100 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Glaucoma, OHT - Ocular Hypertension
Interventions: Timolol 0.5% ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 30 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Rochester, Minnesota • Omaha, Nebraska • Columbus, Ohio

Conditions: Renal Insufficiency, Chronic, Hypertension
Interventions: Chlorthalidone, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hypertension
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 21 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cataract, IOL, Glaucoma, Open-Angle
Interventions: Cataract surgery with implantation of trifocal IOL combined with trabecular scaffold; Procedure
Lead sponsor: Vold Vision P.L.L.C; Other
Eligibility: 45 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Diabetes, Heart Disease, Hypertension
Interventions: CARIÑO Project, Enhanced Usual Care; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 35 Years to 70 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Elevated Blood Pressure, Perimenopause
Interventions: Physical activity intervention; Behavioral
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 45 Years to 50 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: High Blood Pressure
Interventions: Coffee; Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 30 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Schizophrenia, Schizoaffective Disorder, Obesity, Hypertension, Smoking
Interventions: Rimonabant, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 55 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 4
States / cities: Baltimore, Maryland • Catonsville, Maryland

Search by objective public record fields.

SASH Study - Sonographic Assessment for Severe Hypertension in Pregnancy

Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure

Diet Intervention for Hypertension: Adaptation and Dissemination to Native Communities

Sildenafil to Treat HIV-Associated Pulmonary Hypertension

Safety and Intraocular Pressure (IOP) Lowering Efficacy of Low Dose Travoprost

CRICKET Study, Coronary Calcium Scores in Patients With Chronic Kidney Disease

Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia (FETO)

A ED-based Intervention to Improve Antihypertensive Adherence

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Improving Medication Adherence in Hypertensive Patients

Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope

Vascular Effects of High-Salt After Preeclampsia

Antihypertensive Mechanisms of Minocycline in Resistant Hypertension

Internet Intervention to Improve Rural Diabetes Care

SmartSystem Virtual Reality Headset Perimeter Versus Humphrey HFA-III Perimeter

Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance

Chlorthalidone in Chronic Kidney Disease

Perioperative Blood Pressures and Chronic Hypertension

Visual Outcomes With a Trifocal IOL in Subjects With Open-angle Glaucoma

Miami Healthy Heart Initiative a Behavioral Study on Cardiovascular Risk Factors

No Time to Pause: Physical Activity to Improve Health of Midlife Hispanic Women

Effects of High Caffeine Content Coffee on Blood Pressure in Young Adults

The Effects of Rimonabant, on Weight and Metabolic Risk Factors